MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Venture Capital: Northwest
Venture Capital & Angel Investors: Washington
Venture Capital: Washington
Washington State Life Sciences Discovery Fund (LSDF)
Omeros Corporation (NASDAQ:OMER)*
Organization & Developments: Omeros
Parents
Omeros Corporation (NASDAQ:OMER)*
Children
*Clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.
*Most clinically advanced product candidates are derived from our proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures
*The money is to help Omeros continue its quest to make it possible for drug developers to make treatments against more than 100 currently inaccessible protein targets.
*Treatment to reduce pain & recovery from knee surgery
2019: Nice Confirmation From Omeros - Bret Jensen
2019: Omeros Most Excellent Quarter_seekingalpha.com
2019: Omeros: No Partner - No Money - Omeros Corporation (NASDAQ:OMER)
2020: Omeros_Looking To Book 30% Plus Gain By August_mcusercontent.com
2020: Omeros: 2 Major Catalysts On The Horizon_seekingalpha.com
2020: Omeros: Ending 2020 On Some High Notes
2020: Omeros: Some Concerns Remain... As Do Opportunities
2020: Omeros' COVID-19 Opportunity And Challenges
2021: Omeros: On A Tear, More To Come
2021: Omeros: What's Left
2022: Biotech Analysis Central Preview Series: Omeros Corporation_ seekingalpha.com
2022: FDA granted Orphan Drug Designation to OMS906 for the treatment of the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH)
2022: Omeros: FDA Appeal On Narsoplimab And Several 2023 Catalysts On Deck_ seekingalpha.com
2022: Omeros: On Death's Door_seekingalpha.com
2022: Omeros: Taking It To The Max Oct. 05, 2022 1:23 AM ETOmeros Corporation (OMER)15 Comment_ seekingalpha.com
2023: Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price
2023: Omeros: Why It Is Worthwhile To Bet On Narsoplimab_ seekingalpha.com
2024: FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
2024: Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates_seekingalpha.com
2024: Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns
2024: Omeros: Still Worth A Look Despite Narsoplimab Woes
2025: Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
2025: Omeros: Deja Vu All Over Again (Rating Downgrade)
2025: Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster
Organization & Developments: Omeros (Archives 2015-2017)
Organization & Developments: Omeros (Archives 2018)
Jumps
*Key People: Omeros
Finance & Acquisitions: Omeros